BIO Comments to Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (NIST–2023–0008), 88 Fed. Reg. 85593
February 7, 2024
On behalf of its member companies and organizations, the Biotechnology Innovation Organization (“BIO”) extends its appreciation to NIST for considering these comments in response to the agency’s Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (the “draft framework”).
On behalf of its member companies and organizations, the Biotechnology Innovation Organization (“BIO”) extends its appreciation to NIST for considering these comments in response to the agency’s Draft Interagency Guidance Framework for Considering…
On behalf of its member companies and organizations, the Biotechnology Innovation Organization (“BIO”) extends its appreciation to NIST for considering these comments in response to the agency’s Draft Interagency Guidance Framework for Considering the Exercise of March-In Rights (the “draft framework”).